As scientists learn more about COVID-19, it has become clear that the virus especially impacts those with existing medical conditions, such as kidney disease.
Kidney Transplant Program
165 Cambridge Street, Suite 301
Boston, MA 02114
Hours: Monday-Friday, 8:30 am-5:00 pm
Additional Clinic Locations
Massachusetts General Hospital
1750 Elm Street, Suite 201A
Manchester, NH 03104
Massachusetts General Hospital
38 Tyler Street, 2nd Floor
Nashua, NH 03060
Mass General/North Shore
102-104 Endicott Street
Danvers, MA 01923
Cooley Dickinson Hospital
30 Locust Street
Northampton, MA 01060
Explore This Treatment Program
About Our Program
A pioneer in organ transplant since 1963, the Adult Kidney Transplant Program at the Massachusetts General Hospital Transplant Center employs leading-edge medical and surgical technology to provide individualized care for patients with chronic kidney disease. Our expert surgeons have performed more than 3,000 kidney transplants, and have achieved some of the best graft and patient survival rates in the country. In 2017, 40% of patients receiving kidney transplants at Mass General never needed a single dialysis treatment prior to transplant, which is more than twice the national average.
Learn about our programs:
Kidney transplant patients typically require lifelong immunosuppressive medications to prevent their immune systems from attacking the new organ. However, our ground-breaking research is allowing some patients to live drug-free after transplant. We also offer options for highly sensitized patients, patients with incompatible living donors, and patients with challenging medical or surgical issues.
Leadership in Kidney Transplantation
We have consistently led the field in tolerance or the acceptance of transplanted organs without long-term immunosuppression. We performed the first successful tolerance induction for renal allografts in patients with multiple myeloma in 1998. We initiated the first ITN-sponsored clinical tolerance trials for adults in 2001 and performed the first successful tolerance induction in mismatched renal transplant recipients in 2008.
High Kidney Transplant Volumes
Mass General performs significantly more kidney transplants than other Massachusetts institutions. Our high volume of kidney transplants—and skilled team of kidney transplant surgeons, anesthesiologists, nurses and social workers who guide patients through every stage of care—help us to attain excellent results in treating patients who need a kidney transplant. Learn more.
Advanced Evaluation, Multidisciplinary Care
All our patients receive integrated, comprehensive care to treat chronic renal failure, beginning with a careful assessment and discussion with the patient to ensure that transplantation is his/her best treatment option. Candidates work with a transplant coordinator, who participates in the initial evaluation, gathers medical information and previous test results. The transplant coordinator also manages the patient’s full evaluation, which includes patient education, medical, surgical and psychosocial evaluation, and transplant-specific testing.
Kidney transplant candidates are placed on the national United Network for Organ Sharing (UNOS) waiting list, which manages the distribution of organs nationwide.
Care at Your Convenience
The Mass General Kidney Transplant Program also conducts a monthly evaluation clinic at four locations throughout New England. Please ask your patient service coordinator for more information on scheduling an appointment at one of these convenient locations.
Transplantation for Incompatible Donor-recipient Pairs
Mass General is a leader in transplanting patients whose live donor is incompatible with them, either because of blood group or anti-HLA antibodies. We offer:
- Desensitization therapy, in which antibodies are removed from the recipient in advance of transplantation. Mass General has performed dozens of these procedures over the last 10-15 years. The success of this approach was recently described in a New England Journal of Medicine article
- Paired Kidney Exchange, through the National Kidney Registry or UNOS. These transplants are sometimes called “swap” programs, in which a recipient’s incompatible donor donates to someone else (often in another city), while their recipient receives a kidney from another, compatible donor
Living Donor Evaluation
Those interested in living kidney donation can contact our donor coordinator for a confidential conversation to learn more, without any commitment to donation. Medical, surgical and psychosocial evaluation begins only after a prospective donor is fully educated and has consented to donate, and candidates may withdraw from the donation process at any time.
After transplantation, patients are followed by our team of surgeons, nephrologists and nurses who manage the post-transplant needs of the patient, including communication with the patient’s primary care physicians and referral to other specialists, as needed.
Become a Donor
Donating a kidney to another individual is an act of great kindness. Nearly half of the kidneys transplanted at Mass General are given by living donors—family members, friends, co-workers and donors who are unknown to the recipient.
Living donor kidney transplants have several benefits, including:
- Eliminates the need for placement on a waiting list
- Better short and long-term survival rates
- Recipient knows the donor, his/her lifestyle and medical history
- Shortens the wait time for others on the waiting list
- Transplant surgery can be scheduled at the donor and recipient's convenience
- Fewer recipients require temporary dialysis after a living donor transplant compared to a decreased donor transplant
Individuals who wish to become living kidney donors undergo a three-part evaluation process, as described below. Our dedicated donor coordinators guide potential donors through each step, keeping them informed of testing and evaluation results. Typically, the recipient's insurance will cover the cost of the evaluation and surgery.
Phase One: Living Donor Health Questionnaire
- Donor evaluation begins with the prospective donor submitting a completed living donor health questionnaire to determine their overall health status and candidacy to donate
- Once a completed living donor health questionnaire is received, the donor will receive a confirmation email with further instructions
Phase Two: Multidisciplinary Team Evaluation (Part 1)
- Candidates come to Mass General for a half-day donor evaluation visit. This visit includes an educational session, a meeting with the donor coordinator, social worker and a nephrologist (a doctor who specializes in kidney care), who reviews the candidate’s medical history and conducts a physical examination
- The physical examination includes blood work, urine tests and an electrocardiogram (EKG)
- After the visit, the donor candidate will complete a 24-hour urine collection and have additional blood tests, which can be completed at a laboratory close to the candidate’s home. Based on the medical history and physical exam, other tests may be necessary and can often be scheduled close to the candidate’s home
Phase Three: Multidisciplinary Team Evaluation (Part 2)
- The donor candidate returns to Mass General for a computed tomography (CT) scan of the kidneys and blood vessels, as well as any other necessary consultations
- This visit includes meeting with the surgeon to discuss the candidate’s ability to donate, as well as the surgical procedure and hospital experience
- The donor candidate also meets with the independent donor advocate, who is a social worker that works with the donor candidate to ensure that his or her best interests are represented and that decisions made are to the benefit of the donor
Once all tests are complete, the donor’s candidacy is reviewed at the Mass General Transplant Center’s multidisciplinary kidney transplant selection meeting. If the donor is approved, donation surgery can be scheduled on a date that is convenient for both the donor and recipient.
New Immunosuppression Regimens
Transplant patients take medications to keep their immune system from rejecting their new organs. The standard medications used today are effective but have many side effects, including toxicity to the transplanted kidney which tends to shorten the lifespan of the organ. Less toxic drugs have been developed to support better long-term kidney function. The MGH Transplant Center is one of many academic medical centers conducting clinical trials using these newer immunosuppressive agents. ]
- Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
In spite of advances over the last 50 years in anti-rejection medications, the side effects of long-term immunosuppressive therapy remain a major problem for post-transplant patients. The MGH Transplant Center has been a leader in developing procedures that allow transplant patients to take fewer or no medications. These protocols continue to improve in living donor kidney transplantation and will soon expand to include patients who receive deceased donor kidneys as well.
The absence of insulin-producing cells in the body results in type 1 diabetes. Islet transplantation replaces the insulin-producing cells of the pancreas without the risks of major abdominal surgery that come with a whole organ pancreas transplant. The MGH Transplant Center is one of the few centers in the country, and the only in New England, that can isolate and transplant pancreatic islets. Islet transplantation is an option for patients who have had a previous kidney transplant and for those without kidney disease.
- Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Infections After Transplant
Infections after transplant are relatively common, especially within the first year. All transplant patients receive prophylactic therapy in order to prevent such infections. The MGH Transplant Center is participating in clinical trials which utilize different medications and monitoring of infections in order to prevent and treat post-transplant infections.
- Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients
- Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
HOPE Act: HIV+ Donors for HIV+ Recipients
Until 2015, transplanting organs from HIV positive donors was not allowed under the National Organ Transplant Act of 1984. However, since HIV treatments have improved and HIV positive transplant recipients have done well after transplant, the HIV Organ Policy Equity (HOPE) Act was recently passed.
The HOPE Act allows organs from HIV positive donors to be transplanted into HIV positive recipients. These are organs that would have been discarded before the HOPE Act was passed. The MGH Transplant Center is one of the few hospitals in the United States doing these transplants.
Hepatitis C Positive Kidney Transplant for Hepatitis C Negative Recipients
Currently there are more available hepatitis C positive deceased donors in New England than there are recipients. With the arrival of new anti-viral agents Hepatitis C cure rates are almost at 100%. Under a clinical trial protocol we are now transplanting kidneys from donors who are positive for hepatitis C virus into select recipients who are not infected with the hepatitis C virus. Patients who enter into this trial receive immediate pre-emptive treatment for Hepatitis C. This will allow these selected recipients to be receive a transplant more quickly, avoiding many consequences of prolonged time on the waitlist and dialysis related complications.
- Aug | 18 | 2020
A medida que los científicos van conociendo más sobre el COVID-19, se ha hecho evidente que el virus impacta especialmente a aquellos con condiciones médicas existentes, como la enfermedad renal.
- Mar | 9 | 2020
Partial restoration of kidney function by transplant was significantly associated with improved cardiovascular functional reserve without major change in ventricular structural features.
- Mar | 6 | 2020
With the addition of high-dose cyclophosphamide to graft-versus-host disease prophylaxis, simultaneous stem cell/kidney transplantation is feasible for selected patients who have partially HLA-matched donors.
- May | 16 | 2019
Basic and clinical investigations have identified a role for kidney-derived glycerol-3-phosphate in stimulating circulating fibroblast growth factor 23 after acute kidney injury.
- Nov | 21 | 2018
As an elected ECOR representative, Sylvie Breton, PhD, has advocated for new programs and initiatives to support researchers at Massachusetts General Hospital.